Advanced Glycation End Products and Cardiovascular Disease

被引:57
|
作者
Peppa, Melpomeni [1 ]
Raptis, Sotirios A. [1 ]
机构
[1] Attikon Univ Hosp, Res Inst & Diabet Ctr & Hel lenic Natl Diabet Ctr, Dept Internal Medicine Propaedeut 2, Endocrine Unit, Athens, Greece
关键词
Cardiovascular disease; Atherosclerosis; Oxidative stress; Inflammation; Arterial stiffening; Endothelium; Diet; Advanced glycation end products; AGEs; AGE-receptors; AGE-inhibitors; AGE-breakers;
D O I
10.2174/157339908784220732
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Advanced glycation end products [AGEs] seem to play an important role for the development and/or progression of CVD mainly through induction of oxidative stress and inflammation. AGEs are a heterogenous group of molecules formed by the nonenzymatic reaction of reducing sugars with amino acids of proteins, lipids and nucleic acids. Recent studies suggest that in addition to those endogenously formed, diet constitutes an important exogenous source of AGEs. Diet-derived AGEs contribute to the whole body AGE pool and the AGE-related pathology. Recent in vitro and in vivo studies revealed significant correlations between diet-derived AGEs and several risk factors and/ or markers of CVD, suggesting the dietary AGEs restriction as a promising therapeutic intervention.
引用
收藏
页码:92 / 100
页数:9
相关论文
共 50 条
  • [21] Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products
    Carroll, Lisa
    Hannawi, Suad
    Marwick, Thomas
    Thomas, Ranjeny
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2006, 156 (1-2) : 42 - 52
  • [22] Intracellular toxic advanced glycation end-products in cardiomyocytes may cause cardiovascular disease
    Takata, Takanobu
    Sakasai-Sakai, Akiko
    Ueda, Tadashi
    Takeuchi, Masayoshi
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [23] Advanced Glycation End Products: key player of the pathogenesis of atherosclerosis
    Singh, Sanjiv
    Siva, Boddu Veerabadra
    Ravichandiran, V.
    GLYCOCONJUGATE JOURNAL, 2022, 39 (04) : 547 - 563
  • [24] Advanced glycation end products and insulin resistance
    Unoki, Hiroyuki
    Yamagishi, Sho-ichi
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) : 987 - 989
  • [25] Advanced glycation end products in clinical nephrology
    Kalousová, M
    Zima, T
    Tesar, V
    Stípek, S
    Sulková, S
    KIDNEY & BLOOD PRESSURE RESEARCH, 2004, 27 (01) : 18 - 28
  • [26] Advanced Glycation End Products in the Pathogenesis of Psoriasis
    Papagrigoraki, Anastasia
    Maurelli, Martina
    del Giglio, Micol
    Gisondi, Paolo
    Girolomoni, Giampiero
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (11):
  • [27] Advanced Glycation End Products and Diabetic Complications
    Singh, Varun Parkash
    Bali, Anjana
    Singh, Nirmal
    Jaggi, Amteshwar Singh
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2014, 18 (01) : 1 - 14
  • [28] Receptor for advanced glycation end products (RAGE) gene polymorphism and cardiovascular disease in end-stage renal disease patients
    Buraczynska, Monika
    Zaluska, Wojciech
    Buraczynska, Kinga
    Markowska-Gosik, Dorota
    Ksiazek, Andrzej
    HUMAN IMMUNOLOGY, 2015, 76 (11) : 843 - 848
  • [29] Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women
    Semba R.D.
    Ferrucci L.
    Sun K.
    Beck J.
    Dalal M.
    Varadhan R.
    Walston J.
    Guralnik J.M.
    Fried L.P.
    Aging Clinical and Experimental Research, 2009, 21 (2) : 182 - 190
  • [30] Fluorophores advanced glycation end products (AGEs)-to-NADH ratio is predictor for diabetic chronic kidney and cardiovascular disease
    Ciobanu, Dana M.
    Olar, Loredana E.
    Stefan, Razvan
    Veresiu, Ioan A.
    Bala, Cornelia G.
    Mircea, Petru A.
    Roman, Gabriela
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (07) : 893 - 897